Sun Pharma and Merck enter into licensing agreement for tildrakizumab
Merck and Sun Pharmaceutical announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. September 17, 2014